Anebulo Pharmaceuticals, Inc. ANEB
0.33
0.00
0.00%
as of 25 Sep
- Market cap
- $17.6M
- P/E
- 0.0×
Follow ANEB
Growth Flags
show if company had growth for consecutive years
| Older periods | Mar '25 | Jun '25 | Sep '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
25.29 | 24.53 | 10.93 | 6.24 |
Net Debt/EBITDA |
8.06 | 5.03 | 4.62 | 3.47 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.77 | 0.59 | 0.66 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.04) | (0.05) | (0.03) | (0.03) | |
Cash per Share |
0.32 | 0.34 | 0.25 | 0.22 | |
Shareholders Equity per Share |
0.33 | 0.34 | 0.24 | 0.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.33 | 0.34 | 0.24 | 0.19 | |
Free Cash Flow |
(1.60) | (1.65) | (1.27) | (1.31) | |
Working Capital |
13.26 | 11.47 | 9.57 | 7.79 | |
Net Current Asset Value |
13.26 | 11.47 | 9.57 | 7.79 | |
| Other line items | |||||
Quick Ratio |
24.32 | 23.99 | 10.75 | 6.12 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.05) | (0.03) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | 0.04 | 0.02 | 0.15 | |
Average Payables |
0.41 | 0.19 | 0.43 | 0.44 | |
Average Assets |
10.00 | 8.11 | 6.58 | 12.63 | |
Average Common Equity |
9.22 | 7.74 | 5.82 | 11.45 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates